The Journal of Cell BiologyCell BiologyPeer-reviewed journal article
Differential cell-ECM interaction of rhabdomyosarcoma subtypes regulated by PAX3-FOXO1
Antonios ChronopoulosiD, Ivan ChaveziD, Chandra Kaladhar VemulaiD, Nikhil MittaliD, Vic ZamlootiD, Yuanzhong PaniD, Sangyoon J. HaniD, JinSeok ParkiD
Abstract
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma, with two subtypes: Fusion-positive RMS (FPRMS), which has the PAX3-FOXO1 fusion gene, and fusion-negative RMS (FNRMS). Despite their distinct characteristics, treatments mainly rely on conventional chemotherapies without considering these differences. This study highlights that FNRMS cells exhibit significantly heightened interaction with the extracellular matrix (ECM) compared to FPRMS cells. Using single-cell RNA sequencing of skeletal muscle tissues and RNA sequencing of RMS samples, we identified the upregulation of genes related to cell-ECM interaction and TGF{beta} signaling in FNRMS compared to FPRMS. We also confirmed enhanced cell-ECM interaction stimulated by TGF{beta} signaling in FNRMS cells, using confocal reflection microscopy to monitor dynamic cell-ECM interaction and a live-cell sensor to quantitatively assess TGF{beta} signaling activity. Additionally, we discovered that the PAX3-FOXO1 fusion gene, characteristic of FPRMS, stimulated nitric oxide synthesis, which suppresses TGF{beta} signaling and reduces cell-ECM interaction. These findings suggest that PAX3-FOXO1 determines the diminished cell-ECM interactions in FPRMS. Experimental data show higher sensitivity of FNRMS to cell-ECM interaction disruption and TGF{beta} inhibition. Furthermore, the diminished cell-ECM interaction in FPRMS, allowing cells to survive in the ectopic environment through circulation, may partly explain its higher metastatic potential compared to FNRMS.
- organism: human
- assay: scRNA-seq
- assay: bulk RNA-seq
- assay: imaging
- research focus: cell-cell communication
- research focus: differential expression
- approach: statistical model
- Citations
- 1
- FWCI
- 0.41
- Field percentile
- top 40%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Fusion transcription factor dosage controls cell state in rhabdomyosarcoma
Rachel A. Hoffman, Meng Wang, … Benjamin Z. Stanton·bioRxiv·May 16, 2025
- RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma
Elizabeth A. Mendes, Aanandi Munshi, … Corinne Mary Linardic·bioRxiv·Jul 21, 2025
- Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma.
J. DeMartino, M. T. Meister, … J. Drost·bioRxiv·Jul 15, 2022
- Comparative modes of chromatin engagement by PAX::FOXO1 fusions in rhabdomyosarcoma
Alexi M Tallan, Jack P. Kucinski, … Benjamin Z. Stanton·bioRxiv·Feb 19, 2026
- Myogenic and neural transcriptional circuitry determines PAX3::FOXO1 driven initiation of rhabdomyosarcoma
Bradley T. Stevens, Yang Zhang, … Mark E. Hatley·bioRxiv·Oct 29, 2026
- Single-cell mapping of tumor heterogeneity in pediatric rhabdomyosarcoma reveals developmental signatures with therapeutic relevance
S. G. Danielli, E. Porpiglia, … B. W. Schäfer·bioRxiv·Apr 20, 2022